{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"High Level Meeting on AMR at the United Nations: A Debrief ","description":"The second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR research and antimicrobial development.  Topics discussed: The political implications of the UN declaration on AMR. Comment of the scientific and public health impact of the declaration Elaborate on future antimicrobial research and development Guests: John Rex, MD. Chief Medical Officer, F2G Ltd; Operating Partner, Advent Life Sciences Prabha Fernandes, PhD. Board Member of GARDP (Global Antibiotic Research and Development Partnership). Links: HLM on AMR at UNGA: The end of the beginning 29 April 2024: \u201cR&D Implications: Global Burden of Disease is 28% Infectious!\u201d 27 Sep 2024: \u201cWithout action, AMR costs go from $66b to $159b\/yr by 2050\u201d This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal.  Visit asm.org\/aac to browse issues and\/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org\/joinasm to sign up. ","author_name":"Editors in Conversation","author_url":"https:\/\/asm.org\/eic\/","html":"